The 2021 Self-Blinding Study: Why Expectancy Matters

Written by Microdose News Editorial TeamNovember 8, 2026Research2 min read

Key takeaways

Both groups improved from baseline.
Between-group differences did not support broad psychological benefit.
At-home self-blinding has important limitations.

A 2021 eLife study used a self-blinding approach to investigate microdosing in everyday settings. Its central finding was that both active and placebo groups improved over time without clear between-group differences in psychological outcomes.

What was studied

Szigeti and colleagues reported a four-week citizen-science study involving 191 people already microdosing. Participants supplied their own substances and followed procedures intended to conceal whether a given condition involved active material or placebo.

That approach made an at-home study possible, but it was not the same as an investigator-controlled trial using a standardized product. The research needs to be understood in its original context.

The main result

Psychological measures improved from baseline in both groups. The researchers did not find significant between-group differences on those outcomes, and participants’ beliefs about their assignment were important to interpreting reported changes.

This is evidence against assuming that every improvement reported during a microdosing routine reflects a pharmacological effect. It does not mean that participants were dishonest or that their experiences were unimportant.

Why blinding is difficult

If someone detects a sensation and guesses the active condition, expectations can influence subsequent ratings. Self-report measures are especially sensitive to this problem, making condition guesses a useful part of the analysis.

At-home substance variability and participant selection add further limitations. The study does not establish a treatment outcome for people with a specific diagnosed disorder.

What readers should take away

The paper is a research milestone from March 2021, not a new trial announcement. It illustrates why comparison groups matter and why improvement from baseline is not enough to establish causation.

Read it alongside the 2022 controlled psilocybin study rather than treating one study as the final answer to the field.

Sources and further reading

Explore our research resources for help checking original sources.

Medical information: This article is for education, not diagnosis or treatment. Discuss health decisions with a qualified clinician. Do not change prescribed treatment based on this article.

The accompanying picture is an illustrative editorial image, not a photograph of the cited study or its participants.